

Curriculum Vitae

Claus F. Vogelmeier Professor, Dr. med., d.o.b. January 9th, 1956

University Education

1993 Habilitation Internal Medicine, Ludwig-Maximilians University Munich

1984 Doctorate Medicine, Ludwig-Maximilians University Munich

1975-1982 Studies of Medicine, Ludwig-Maximilians University Munich

Scientific Career

Since 2001 Professor of Medicine and Head, Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-University Marburg

1998-2001 Chief, Section for Pulmonary Diseases, Department of Medicine, Ludwig-Maximilians University Munich

1989 - 1994 Internship and Residency, Department of Medicine, Ludwig-Maximilians University Munich

1987 - 1989 postdoctoral fellowship at the Pulmonary Branch, NHLBI, National Institutes of Health, Bethesda, MD, USA

1984 - 1987 Internship and Residency, Department of Medicine, Ludwig-Maximilians University Munich

Awards and Honors

2018-2019 President of the German Society for Internal Medicine (DGIM)

2018 Honorary title "Fellow of the American Respiratory Society"

2017 Honorary membership of the Austrian Society of Pulmonary Medicine (ÖGP)

Since 2015 Chairman of the German Lung Foundation

Since 2014 Fellow of the European Respiratory Society (FERS)

Since 2010 Member/Chair of the Science Committee of the Global Initiative for Chronic Obstructive Lung Disease – GOLD

2009 - 2011 President of the German Respiratory Society

Since 2008 Chairman of the German Asthma and COPD Network

2004-2010 member of the board of the German Research Foundation (DFG)

Since 2002 member of the board of directors of "Deutsche Atemwegsliga"

1993 Curt-Dehner-medal 1993 for emphysema research

11/87 - 11/89 grant by the German Research Foundation (DFG) for post doctoral fellow training

1975-82 grant for gifted students, Bayerisches Staatsministerium für Unterricht und Kultus

Citation Record

Total citations: 37,468; h-index:80; h-index since 2017: 59 (Google Scholar September 8th, 2022)

Top-10 selected Publications

Celli B, Fabbri L, Criner G, Martinez FJ, Mannino D, **Vogelmeier C**, Montes de Oca M, Papi A, Sin DD, Han MK, Agusti A. Definition and Nomenclature of Chronic Obstructive Pulmonary Disease: Time for its Revision. *Am J Respir Crit Care Med*. 2022 Aug 1. doi: 10.1164/rccm.202204-0671PP.

Kuhnert S, Mansouri S, Rieger MA, Savai R, Avci E, Díaz-Piña G, Padmasekar M, Looso M, Hadzic S, Acker T, Klatt S, Wilhelm J, Fleming I, Sommer N, Weissmann N, **Vogelmeier C**, Bals R, Zeiher A, Dimmeler S, Seeger W, Pullamsetti SS. Association of Clonal Hematopoiesis of Indeterminate Potential with Inflammatory Gene Expression in Patients with COPD. *Cells*. 2022 Jul 5;11(13):2121. doi: 10.3390/cells11132121.

Waschki B, Alter P, Zeller T, Magnussen C, Neumann JT, Twerenbold R, Sinning C, Herr C, Kahnert K, Fähndrich S, Blankenberg S, Rabe KF, Welte T, Jörres RA, **Vogelmeier CF**, Bals R, Watz H; German COSYCONET Cohort. High-sensitivity troponin I and all-cause mortality in patients with stable COPD: an analysis of the COSYCONET study. *Eur Respir J*. 2020 Feb 27;55(2):1901314. doi: 10.1183/13993003.01314-2019.

Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Criner GJ, Frith P, Halpin DMG, Han M, López Varela MV, Martinez F, Montes de Oca M, Papi A, Pavord ID, Roche N, Sin DD, Stockley R, Vestbo J, Wedzicha JA, **Vogelmeier C**. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. *Eur Respir J*. 2019 May 18;53(5):1900164. doi: 10.1183/13993003.00164-2019.

Criner GJ, Celli BR, Brightling CE, Agusti A, Papi A, Singh D, Sin DD, **Vogelmeier CF**, Sciruba FC, Bafadhel M, Backer V, Kato M, Ramírez-Venegas A, Wei YF, Bjermer L, Shih VH, Jison M, O'Quinn S, Makulova N, Newbold P, Goldman M, Martin UJ; GALATHEA Study Investigators; TERRANOVA Study Investigators. Benralizumab for the Prevention of COPD Exacerbations. *N Engl J Med*. 2019 Sep 12;381(11):1023-1034. doi: 10.1056/NEJMoa1905248.

Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DM, López Varela MV, Nishimura M, Roche N, Rodriguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agustí A. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. *Am J Respir Crit Care Med*. 2017 Mar 1;195(5):557-582. doi: 10.1164/rccm.201701-0218PP.

Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, Thach C, Fogel R, Patalano F, **Vogelmeier CF**; FLAME Investigators. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. *N Engl J Med*. 2016 Jun 9;374(23):2222-34. doi: 10.1056/NEJMoa1516385.

Vogelmeier CF, Bateman ED, Pallante J, Alagappan VK, D'Andrea P, Chen H, Banerji D. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. *Lancet Respir Med*. 2013 Mar;1(1):51-60. doi: 10.1016/S2213-2600(12)70052-8.

Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Mölken MP, Beeh KM, Rabe KF, Fabbri LM; POET-COPD Investigators. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. *N Engl J Med*. 2011 Mar 24;364(12):1093-1103. doi: 10.1056/NEJMoa1008378.

Vogelmeier C, Hubbard RC, Fells GA, Schnebli HP, Thompson RC, Fritz H, Crystal RG. Anti-neutrophil elastase defense of the normal human respiratory epithelial surface provided by the secretory leukoprotease inhibitor. *J Clin Invest*. 1991 Feb;87(2):482-8. doi: 10.1172/JCI115021.